RAINMED MEDICAL LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.153 HKD | -7.27% |
|
-11.05% | -64.42% |
| 03-28 | Rainmed Medical Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Rainmed Medical Limited announces Change of Principal Place of Business in Hong Kong | CI |
| Sales 2021 | 81.2M 11.21M 87.73M 15.32M | Sales 2022 | 83.6M 11.54M 90.32M 15.77M | Capitalization | 1.6B 221M 1.73B 302M |
|---|---|---|---|---|---|
| Net income 2021 | -634M -87.5M -685M -120M | Net income 2022 | -1.35B -186M -1.45B -254M | EV / Sales 2021 * | - |
| Net Debt 2021 | 819M 113M 885M 155M | Net cash position 2022 | 550M 75.9M 594M 104M | EV / Sales 2022 | 12.5 x |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
-0.91
x | Employees | 406 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 25.86% |
More Fundamentals
* Assessed data
More news
| 1 day | -7.27% | ||
| 1 week | -11.05% | ||
| Current month | -30.45% | ||
| 1 month | -33.19% | ||
| 3 months | -55.65% | ||
| 6 months | -75.32% | ||
| Current year | -64.42% |
1 week
0.14
0.17
1 month
0.140.22
Current year
0.140.46
1 year
0.141.24
3 years
0.146.10
5 years
0.146.10
10 years
0.146.10
| Managers | Title | Age | Since |
|---|---|---|---|
Yong Hui Lyu
CEO | Chief Executive Officer | 47 | 21-12-09 |
Yun Fei Huo
CEO | Chief Executive Officer | 46 | 13-12-31 |
Liang Zhang
DFI | Director of Finance/CFO | 41 | 21-12-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shuen Kong Liu
BRD | Director/Board Member | 52 | 21-12-09 |
Ho Man Li
BRD | Director/Board Member | 41 | 21-12-09 |
Yun Fei Huo
CEO | Chief Executive Officer | 46 | 13-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.153 | -7.27% | 191,000 |
| 24-04-25 | 0.165 | 0.00% | 20,000 |
| 24-04-24 | 0.165 | 0.00% | 0 |
| 24-04-23 | 0.165 | 0.00% | 10,000 |
| 24-04-22 | 0.165 | -4.07% | 66,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am
More quotes
Rainmed Medical Ltd is a China-based investment holding company. The Company is primarily engaged in research and development, manufacturing and commercialization of medical instrument related to coronary angiography-derived fractional flow reserve (caFFR) system and coronary angiography-derived index of microvascular resistance (caIMR) system. The Companyâs core products, caFFR system and caIMR system, are innovative medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (CAD). They are designed to eliminate the usage of pressure wires, significantly reduce the risk of technical errors and operation time, and improve physiological assessment. The Company mainly operates its businesses in the domestic and overseas markets.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -64.42% | 22.82M | |
| +4.55% | 3.48B | |
| -12.80% | 156M | |
| -15.69% | 81.85M | |
| +30.43% | 59.71M |
- Stock Market
- Equities
- 2297 Stock
